Charts Elicera Therapeutics AB

Stocks

Delayed Nasdaq Stockholm 03:56:00 2026-10-23 EDT			5-day change	1st Jan Change
2.820 ^SEK	+0.71%		-2.59%	-45.98%

10-12	Elicera Therapeutics AB Completes Phase I Part of Carma Study of Elc-301 and Reports Complete Metabolic Response in 8 of 12 Patients	CI
09-17	Elicera Therapeutics to Launch B-cell Lymphoma Therapy's Phase 2a Trial	MT

Nasdaq StockholmSEK

ProRealTime Chart